BTK and non-Hodgkin lymphoma: We would advocate for the clinical trials comparing traditional chemo-immunotherapy with Bendamustine/Rituximab in combination with Bruton's tyrosine kinase (BTK) inhibitors, as was recently examined in a Phase 1/1b trial for untreated and relapsed/refractory non-Hodgkin lymphoma [96] (Table 2).